Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Carebox Health SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your NCT05234567 trial has enrolled 22% Black patients vs 36% target per your protocol diversity plan filed March 2024" (FDA database with specific trial numbers and protocol targets)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, trial NCT numbers.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, contacts already provided, patterns already identified - whether they buy or not.
These messages demonstrate precise understanding of the prospect's current situation and deliver immediate actionable value. Each play is sorted by quality score - the strongest, most defensible plays appear first.
Identify COG institutions running orphan-designated pediatric cancer trials where eligible patients exist at nearby hospitals but are being referred to distant competitors instead of the closer trial site.
You're showing them a fixable referral relationship gap with a specific hospital, specific patient count, and a clear geographic advantage. The complete contact information (name, email, phone) means they can act immediately without needing to reply to you first. This helps them build their referral network and enroll more children - even if they never buy from Carebox.
This play requires access to pediatric oncology referral networks or COG site-level patient flow data showing where diagnoses originate versus where patients ultimately enroll in trials.
This synthesis of referral patterns and geographic proximity is unique to platforms that track patient journeys across institutions.Identify biologics sponsors with Phase II-III trials in therapeutic areas with FDA diversity action plans where trial locations are in high-diversity regions BUT enrollment demographics show significant underrepresentation. Connect them to specific FQHC networks with demonstrated clinical trial enrollment success.
You're providing a specific FQHC network with real patient volume, complete contact information for the decision-maker, and proof of geographic overlap with their existing trial sites. The prospect can make one phone call today to potentially close their diversity gap. This helps them meet FDA requirements and helps underrepresented communities access experimental treatments - all without requiring a reply to you first.
This play requires partnerships with FQHC networks providing clinical trial enrollment data and referral patterns by geography.
Combined with public trial site data to identify geographic overlaps. This network intelligence is unique to platforms that facilitate community health center partnerships.Alert rare disease drug sponsors when their trial has diversity gaps AND show them the exact underrepresented patient pool available but not being recruited. Cross-reference trial sites with community hematology clinic locations and patient populations.
You're providing specific actionable leads at their trial sites with complete contact information (clinic names, contact people, phone numbers) plus anonymized patient profiles. They can start outreach immediately. This directly addresses their protocol diversity targets and helps sickle cell patients access potentially curative experimental treatments - all before they ever respond to you.
This play requires partnerships with community hematology clinics or patient registries providing anonymized patient cohort data for trial matching.
Combined with public trial site locations to identify geographic proximity. This patient discovery capability is unique to platforms with healthcare provider networks.Cross-reference NCI cancer center screening failure records with newly opened trials to identify patients who were previously marked "ineligible" but now match active trials. Show coordinators they can recover wasted screening time by re-contacting these pre-screened patients.
You're showing them they already did the hard work (initial screening) and there ARE eligible patients they can contact immediately. This saves coordinator hours, helps them hit enrollment targets, and helps cancer patients access potentially life-saving trials. The value is immediate and actionable even if they never buy your platform.
This play requires the recipient's historical screening data from your trial management system (patient IDs, screening dates, disposition reasons).
Only works for upselling existing customers or re-engaging former customers, not cold acquisition.Cross-reference biologics trial sites with community health center locations and patient populations. Identify sponsors with significant diversity enrollment gaps and provide them with anonymized patient cohort details and FQHC contacts in their trial catchment areas.
You're providing specific actionable leads at their existing trial sites. The patients are actively seeking clinical trial information (warm leads). This helps them close their diversity gap immediately and avoid BLA delays - even if they don't buy from you. The ask is low-commitment (just send the list).
This play requires partnerships with FQHC networks or community health centers providing anonymized patient cohort data for clinical trial matching (condition, demographics, geographic location, trial interest indicators).
Combined with public trial site data. This patient discovery capability is unique to platforms with community health partnerships.Analyze trial management system logs to identify inefficient coordinator workflows - specifically, repeated outreach attempts to the same "declined" patients with zero conversions. Quantify the wasted time and offer fresh eligible patient leads who haven't been contacted yet.
You're quantifying a specific waste metric (93 coordinator hours) and offering an immediate solution (42 new patients who haven't been burned out by repeated calls). This saves coordinator time, reduces burnout, and helps enroll more cancer patients - all actionable today whether they buy from you or not.
This play requires the recipient's trial management system logs showing coordinator outreach patterns, call attempts, and patient disposition tracking.
Only works for existing customers or re-engaging former customers, not cold acquisition.Cross-reference COG registry diagnosis data with active clinical trials at member institutions. Identify neuroblastoma patients diagnosed at nearby hospitals who match trial eligibility but weren't referred to the prospect's site.
You're showing them a specific number of patients, the exact trial they match (NCT number), and hospital locations. This reveals a fixable referral network gap. The prospect can contact those hospitals immediately to build relationships and improve their referral pathways - actionable value whether they buy from you or not.
This play requires partnership with COG or pediatric oncology registries providing anonymized diagnosis data by geography, disease type, and staging.
Combined with public trial data to match patients to eligibility criteria. This registry access is unique to platforms with COG partnerships.Identify biologics sponsors with Phase II-III trials in therapeutic areas with FDA diversity action plans (oncology, cardiovascular, diabetes) where trial enrollment demographics show significant underrepresentation compared to disease incidence. Highlight the compliance risk before BLA filing deadlines.
You're using specific trial data (NCT number, actual enrollment percentages) against their own BLA filing timeline. The time pressure is real and quantified. However, this play still just identifies the problem without providing the solution, which limits its value unless the recipient buys.
Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data and internal network intelligence to find companies in specific painful situations. Then mirror that situation back to them with evidence or deliver value they can use immediately.
Why this works: When you lead with "Your NCT05234567 trial has enrolled 22% Black patients vs 36% target per your protocol diversity plan" instead of "I see you're hiring for clinical trial roles," you're not another sales email. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources with specific situations. Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable public data or proprietary internal partnerships. Here are the key sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| ClinicalTrials.gov | trial_id, sponsor_name, enrollment_status, location, inclusion_criteria, demographics | Identifying active trials, enrollment gaps, site locations, eligibility criteria |
| NCI-Designated Cancer Centers Directory | center_name, center_type, location, directors, shared_resources | Identifying major cancer research institutions running clinical trials |
| Children's Oncology Group (COG) Member Institutions | institution_name, location, pediatric_oncology_focus | Mapping children's hospitals running pediatric cancer trials |
| FDA Orphan Drug Designation Database | product_name, company_sponsor, indication, designation_date | Identifying rare disease drug sponsors with heightened recruitment urgency |
| National Organization for Rare Disorders (NORD) Member Directory | organization_name, disease_focus, patient_members, geographic_reach | Connecting patient advocacy organizations to rare disease trials |
| FDA Bioresearch Monitoring Information System (BMIS) | clinical_investigator_name, institution, ind_application_id, study_phase | Identifying clinical investigators and trial sites managing patient recruitment |
| Internal Patient Matching Data | patient_demographics, eligibility_matches, referral_patterns, unmatched_patient_pools | Proprietary - identifying eligible patients not yet recruited, referral bottlenecks |
| Internal FQHC Partnership Data | community_health_center_locations, patient_cohorts, enrollment_volume, trial_interest | Proprietary - connecting trials to underrepresented patient populations via community health networks |
| Internal Trial Management System Data | screening_logs, coordinator_workflows, patient_disposition, outreach_attempts | Proprietary - analyzing site performance, coordinator efficiency, screening bottlenecks |